Search

Displaying results 6641 - 6650 of 10000 in total
  1. Drug

    Anisodamine

    go.drugbank.com/drugs/DB11785
    Investigational

    Anisodamine has been investigated for the treatment of Intestinal Diseases.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Talmapimod

    go.drugbank.com/drugs/DB05412
    Investigational

    Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

  3. Drug

    Cefacetrile

    go.drugbank.com/drugs/DB01414
    InvestigationalVet approved

    A derivative of 7-aminocephalosporanic acid.

  4. Drug

    Amolimogene bepiplasmid

    go.drugbank.com/drugs/DB04904
    Investigational

    Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV).

  5. Drug

    Fosifloxuridine nafalbenamide

    go.drugbank.com/drugs/DB14859
    Investigational

    Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).

  6. Drug

    Ieramilimab

    go.drugbank.com/drugs/DB16419
    Investigational

    Ieramilimab is under investigation in clinical trial NCT02460224 (Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.).

  7. Drug

    Saposin C

    go.drugbank.com/drugs/DB17380
    Investigational

    BXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. … Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy.

  8. Drug

    SynOV1.1

    go.drugbank.com/drugs/DB17539
    Investigational

    SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. … SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study).

  9. Drug

    Probiorinse

    go.drugbank.com/drugs/DB15870
    Experimental

    [L16368] This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.[A220193] … Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136.

  10. Drug

    Fasedienol

    go.drugbank.com/drugs/DB04968
    Investigational

    PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.